Clinical Trial Update: Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer [Phase 1]

View source ↗

Summary

This document reports on a Phase 1 high-dose study of Axalimogene filolisbac (ADXS11-001) in women with HPV-related cervical cancer; the trial is completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Axalimogene filolisbac (Axalimogene filolisbac)

Snippet

Sponsor: Advaxis, Inc. | Conditions: Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-05-20